Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.31 | 4.96 | 6.25 | 6.56 | 6.02 | 275967 | 6.17545065 | CS |
| 4 | -1.205 | -15.5183515776 | 7.765 | 8.62 | 6.01 | 385319 | 7.08791594 | CS |
| 12 | -7.95 | -54.7898001378 | 14.51 | 16.11 | 6.01 | 332798 | 9.67063144 | CS |
| 26 | -6.16 | -48.427672956 | 12.72 | 16.11 | 6.01 | 280424 | 11.48803618 | CS |
| 52 | -3.26 | -33.1975560081 | 9.82 | 20.9 | 6.01 | 323667 | 12.90739544 | CS |
| 156 | -3.22 | -32.9243353783 | 9.78 | 20.9 | 2.7 | 416711 | 9.21736097 | CS |
| 260 | -28.67 | -81.3795061028 | 35.23 | 55.36 | 2.7 | 341794 | 15.89652459 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
